Benitec May Change HCV Paradigm Again With Single-Dose, DNA-Directed RNAi
This article was originally published in The Pink Sheet Daily
Executive Summary
The Australian biotech got FDA authorization in January to move its first (dd)RNA candidate, TT-034, into clinical development for hepatitis C. Dosing in a 14-patient, five-cohort, Phase I/IIa study will begin in mid-March and produce final data in about 18 months.
You may also be interested in...
Alnylam Validates Subcutaneous Delivery Technology With Strong Phase I Results
The RNA interference-focused biotech will bring the rest of its pipeline forward with subcutaneous technology now that it has been validated in human studies, but the company will continue to pursue approval of its lead candidate as an infusion product.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.